Suzhou Rigen Biopharma

Rigen Biopharma is a clinical-stage biotechnology company based in Suzhou, China, dedicated to developing next-generation small molecule drugs for cancer treatment. The company focuses on the DNA Damage Response (DDR) pathway and protein homeostasis, specifically targeting deubiquitinating enzymes (DUBs) and other synthetic lethality targets. Its lead candidate, RGN-6024, is a highly selective USP1 inhibitor designed to treat patients with advanced solid tumors, particularly those with BRCA mutations or resistance to PARP inhibitors. Rigen leverages a robust internal R&D platform to advance a pipeline of novel inhibitors through global clinical development. The company is supported by top-tier venture capital firms including Lilly Asia Ventures and Qiming Venture Partners. By targeting the mechanisms that cancer cells use to repair DNA, Rigen aims to provide new therapeutic options for patients with high unmet medical needs.